Lung adenocarcinoma (LUAD) is a malignant tumor of the respiratory system with poor prognosis. Recent studies have revealed that N7-methylguanosine (m7G) methylation is a widespread modification occurring in RNA. But the expression of m7G methylation-related genes in LUAD and their correlations with prognosis are still unclear. In this study, we found 12 m7G methylation-related regulators with differential expression between LUAD and normal lung tissues. According to differentially expressed genes (DEGs), all LUAD cases were separated into two subtypes. The prognostic value of each m7G methylation-related gene for survival was evaluated to construct a multigene signature using The Cancer Genome Atlas (TCGA) cohort. Finally, an m7G methylation-related prognostic signature based on three genes was built to classify LUAD patients into two risk groups. Patients in the high-risk group showed significantly reduced overall survival (OS) when compared with patients in the low-risk group ( < 0.05). The receiver operating characteristic (ROC) curve analysis confirmed the predictive capacity of the signature. The Gene Ontology (GO) functional annotation analysis disclosed that chromosome homeostasis plays an important role in this process. The gene set enrichment analysis (ssGSEA) implied that the immune status was decreased in the high-risk group. To sum up, m7G methylation-related genes play a vital role in tumor immunity and the related signature is a reliable predictor for LUAD prognosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637623 | PMC |
| http://dx.doi.org/10.3389/fgene.2022.998258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RNA methylation and breast cancer: insights into m6A, m7G and m5C.
Mol Biol Rep
November 2024
Department of breast surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Article Synopsis
- - Breast cancer is the most common cancer diagnosed in women globally, characterized by its diverse molecular makeup and complex types, which pose challenges in treatment due to tumor heterogeneity and resistance.
- - Recent research has identified nearly 200 RNA modifications, with methylation playing a crucial role in cancer development, progression, and treatment resistance, particularly the N6-methyladenosine (m6A) modification, which involves key "writers," "readers," and "erasers."
- - The review discusses various RNA methylation types (m6A, m7G, m5C, m1A, and m3C), their effects on tumor behavior, and highlights their potential as therapeutic targets, suggesting they may enhance
Unveiling the role of RNA methylation in glioma: Mechanisms, prognostic biomarkers, and therapeutic targets.
Cell Signal
December 2024
Department of Neurosurgery, Shengzhou People's Hospital (the First Affiliated Hospital of Zhejiang University Shengzhou Branch), Zhejiang, China. Electronic address:
Gliomas, the most prevalent malignant brain tumors in the central nervous system, are marked by rapid growth, high recurrence rates, and poor prognosis. Glioblastoma (GBM) stands out as the most aggressive subtype, characterized by significant heterogeneity. The etiology of gliomas remains elusive.
View Article and Find Full Text PDFBioinformatics analysis and validation of RNA methylation-related genes in osteogenic and adipogenic differentiation of rat bone marrow mesenchymal stem cells.
Biochem Biophys Res Commun
December 2024
Department of Oral Implantology, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, China; Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, China; Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou, China. Electronic address:
Article Synopsis
- The study investigates how RNA methylation impacts the differentiation of bone marrow mesenchymal stem cells (BMSCs) into bone (osteogenic) and fat (adipogenic) cells.
- Researchers analyzed gene expression data to identify differentially expressed RNA methylation genes and performed various bioinformatics analyses to understand their functions and relationships.
- Key findings included the identification of specific RNA methylation regulators affecting osteogenic and adipogenic processes, particularly highlighting the roles of genes like Mettl3 in osteogenesis and Fmr1 in adipogenesis.
A prognostic signature based on genes associated with m6A/m5C/m1A/m7G modifications and its immunological characteristics in clear cell renal cell carcinoma.
Sci Rep
August 2024
Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Article Synopsis
- Clear cell renal cell carcinoma (ccRCC) has a high incidence and mortality rate, and current treatments yield poor prognostic outcomes for patients.
- *Recent research highlights the potential of methylation modifications as molecular targets in ccRCC, identifying 57 methylation-related genes (MRGs) using data from large cancer databases.
- *A Methylation-Related Risk Score (MARS) was developed, which showed significant prognostic value and the ability to predict immune responses and treatment outcomes in ccRCC patients, aiding in more personalized treatment strategies.
Prognostic signature and immune efficacy of mA-, mC-, mA-, mG-, and DNA methylation-related regulators in hepatocellular carcinoma.
J Cancer
June 2024
Department of Special Medical Care, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China.
Hepatocellular carcinoma (HCC) is the main type of primary liver cancer, and its related death ranks third worldwide. The curative methods and progress prediction markers of HCC are not sufficient enough. Nevertheless, little progress has been made in the signature of mA-, mC-, mA-, mG-, and DNA methylation of HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!